- Home
- / Virpax Pharmaceuticals
Virpax Pharmaceuticals
Stock Price
$0.7
2024-10-29
Market Capitalization
$3.4 M
2024-10-29
Virpax Pharmaceuticals Summary
Company Summary
- Overview
- Virpax Pharmaceuticals is a company that develops drugs for pain management. It offers Probudur, a liposomal hydro-gel bupivacaine formulation; Envelta, a molecular envelope enkephalin powder formulation; and NobrXiol, a pharmaceutical-grade cannabidiol intranasal spray powder.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- Berwyn, PA, US | view all locations
- Website
- http://www.virpaxpharma.com
- Cybersecurity rating
Table of Contents
Key People
Christopher M. Chipman, Chief Financial Officer
Jeffrey Gudin, EVP, Chief Medical Officer
Gerald W. Bruce, EVP, Commercial Operations
Operating MetricsView all
Manufacturing Sites
24
FY, 2022
LocationsView all
1 location detected
Berwyn, PA HQ
United States
1055 Westlakes Dr #300
Virpax Pharmaceuticals Financials
Summary Financials
- Net income (FY, 2024)
- ($12.1M)
- Cash (FY, 2024)
- $1.5M
- EBIT (FY, 2024)
- ($12.1M)